TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

By

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

By

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

By

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

By

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

By

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

By

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

By

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

By

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

By

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

By